Abstract
Uterine fibroids are the most common benign tumor in women, and cause many symptoms. The treatment for these tumors has traditionally been surgical. However, a variety of medical therapies are now available for use. These drugs are primarily utilized as preoperative adjunctive therapy to ease the difficulty of surgery. However, some may have potential as long-term medical treatments, allowing the patient to delay or even avoid surgery. Current medications include GnRH analogs, selective estrogen receptor modulators, aromatase inhibitors, progesterone receptor modulators, and a variety of other less thoroughly evaluated medications. In addition, a number of drugs are in development that are designed to attack novel, specific targets in the leiomyoma growth, and maintenance process.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Attardi BJ, Hild SA, Reel JR et al (2000) CDB-4124: a potent antiprogestin with antiovulatory and postcoital antifertility activity [abstract 1293]. Proceedings of the 82nd Annual Meeting of the Endocrine Society; Toronto, Canada
Attardi BJ, Burgenson J, Hild SA et al (2002) CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 188:111–123
Baird DD, Dunson DB, Hill MC et al (2003) High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188:100–107
Bakas P, Liapis A, Vlahopoulos S, Giner M, Logotheti S, Creatsas G, Meligova AK, Alexis MN, Zoumpourlis V (2008) Estrogen receptor alpha and beta in uterine fibroids: a basis for altered estrogen responsiveness. Fertil Steril 90:1878
Barbieri RL, Ryan KJ (1981) Danazol: endocrine pharmacology and therapeutic applications. Am J Obstet Gynecol 141:453–463
Benagiano G, Kivinen ST, Fadini R, Cronje H, Klintorp S, van der Spuy ZM (1996) Zoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid study. Fertil Steril 66:223
Bouchard P, Chabbert-Buffet N, Fauser BC (2011) Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril 96:1175–1189
Brandon DD, Erickson TE, Keenan EJ, Strawn EY, Novy MJ, Burry KA, Warner C, Clinton CM (1995) Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab 80:1876
Bulun SE, Simpson ER, Word RA (1994) Expression of the CYP 19 gene and its product aromatase cytochrome P450 in human uterine leiomyoma tissues and cells in culture. J Clin Endocrinol Metab 78:736
Carr BR, Marshburn PB, Weatherall PT et al (1993) An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 76:1217
Chen W, Ohara N, Wang J et al (2006) A novel selective progesterone receptor modulator Asoprisnil (J 867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 91:1296–1304
Chwalisz K, Garg R, Brenner R, et al (2006) Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs) Repro Biol Endocrinol 4 (suppl 1): S8
Chwalisz K, Larsen L, Mattia-Goldberg C et al (2007) A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 87:1399–1412
Chwalisz K, Surrey E, Stanczyk FZ (2012) The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. Reprod Sci 19:563–571
Coutinho EM, Boulanger GA, Goncalves MT et al (1986) Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen, antiprogesterone. Am J Obstet Gynecol 155:761–767
Coutinho EM, Goncalves MT (1989) Long-term treatment of leiomyomas with gestrinone. Fertil Steril 51:939–946
De Leo V, la Marca A, Morgante G (1999) Short term treatment of uterine fibromyomas with danazol. Gynecol Obstet Invest 47:258–262
Donnez J, Tatarchuk TF, Bouchard P et al (2012a) Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 366:409–420
Donnez J, Tomaszewski J, Vazquez F et al (2012b) Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 366:421–432
Eisenger SH, Bonfiglio T, Fiscella K et al (2005) Twelve-month safety and efficacy of low dose mifepristone for uterine myomas. J Minim Invasive Gynecol 12:227–233
Eisinger SH, Fiscella J, Bonfiglio T (2009) Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol 146:215–218
Eisenger SH, Meldrum S, Fiscella K et al (2003) Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 101:243–250
Esteve JLC, Acosta R, Perez Y et al (2012) Treatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 161:202–208
Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282:637–645
Felberbaum RE, Germer U, Ludwig M et al (1998) Treatment of uterine fibroids with a slow-release formulation of the gonadotropin-releasing hormone antagonist Cetrorelix. Hum Reprod 13:1660
Felberbaum RE, Kupker W, Krapp M et al (2001) Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotropin releasing hormone antagonist (Cetrotide). Reprod Biomed online 3:14
Flierman PA, Oberye JJ, van der Hulst VP, de Blok S (2005) Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix. BJOG 112:638
Friedman AJ (1989) Vaginal hemorrhage associated with degenerating submucous leiomyomata during leuprolide acetate treatment. Fertil Steril 52:152
Friedman AJ, Barbieri RL, Doubilet PM et al (1988) A randomized, double-blind trial of gonadotropin-releasing hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 49:404
Friedman AJ, Thomas PP (1995) Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas? Obstet Gynecol 85:631–635
Fritz MA, Speroff L (2011) Clinical gynecologic endocrinology and infertility. Lippincott Williams and Wilkins, Philadelphia
Gonzalez-Barcena D, Alvarez RB, Ochoa EP et al (1997) Treatment of uterine leiomyomas with leutinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod 12:2028
Grudzien MM, Low PS, Manning PC et al (2010) The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells. Feril Steril 93:1290–1298
Harrison-Woolrych M, Robinson R (1995) Fibroid growth in response to high-dose progestogen. Fertil Steril 64:191–192
Hasson MH, Fouad H, Bahashwan S et al (2011) Toward non-surgical therapy for uterine fibroids: catechol-O-methyl transferase inhibitor shrinks uterine fibroid lesions in the Eker rat model. Hum Reprod 11:3008–3018
Hild SA, Reel JR, Blye RP et al (2000) CDB-4124: anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits. Hum Reprod 15:822–829
Hornstein MD, Surrey ES, Weisberg GW, Casino LA (1998) Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet Gynecol 91:16–24
Ishihara H, Kitawaki J, Kado N et al (2003) Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas. Fertil Steril 79(suppl 1):735–42
Ishikawa H, Reierstad S, Demura M et al (2009) High aromatase expression in uterine leiomyoma tissues of African-American women. J Clin Endocrinol Metab 94:1752–1756
Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T (1989) Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 160:637
Kim D, Ramachandran S, Seung-hee B et al (2008) Induction of growth inhibition and apoptosis in human uterine leiomyoma cells by isoliquiritigenin. Reprod Sci 15:552–558
La Marca A, Musacchio MC, Morgante G et al (2003) Hemodynamic effect of danazol therapy in women with uterine leiomyomata. Fertil Steril 79:1240–1242
Loy CJ, Evelyn S, Lim FK et al (2005) Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-gamma ligand, pioglitazone. Mol Hum Reprod 11:561–566
Malik M, Mendoza M, Payson M et al (2009) Curcumin, a nutritional supplement with antineoplastic activity, enhances leiomyoma cell apoptosis and decreases fibronectin expression. Fertil Steril 91:2177–2184
Meagan M, Grudzien MS, Low P et al (2010) The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells. Fertil Steril 93:1290–1298
Melli MS, Farzadi L, Madarek EO (2007) Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and cabergoline (Dostinex) treatment on uterine myoma regression. Saudi Med J 28:445–450
Minaguchi H, Wong JM, Snabes MC (2000) Clinical use of nafarelin in the treatment of leiomyomas. A review of the literature. J Reprod Med 45:481
Miyake A, Takashe T, Isobe A et al (2009) Repressive effect of the phytoestrogen genestein on estradiol-induced uterine leiomyoma cell proliferation. Gynecol Endocrinol 25:403–409
Neven P, De Muylder X, Van Belle Y (1989) Tamoxifen and the uterus and endometrium. Lancet 1:375
Newton C, Slota D, Yuzpe AA, Tummon IS (1996) Memory complaints associated with the use of gonadotropin-releasing hormone agonists: a preliminary study. Fertil Steril 65:1253–1255
Olive DL (2000) Review of the evidence for treatment of leiomyomata. Environ Health Perspect 108(suppl 5):841–843
Olive DL (2008) Gonadotropin-releasing hormone agonists for endometriosis. N Engl J Med 359:40–46
Otubu JA, Buttram VC, Besch NF, Besch PK (1982) Unconjugated steroids in leiomyomas and tuor-bearing myometrium. Am J Obstet Gynecol 143:130
Palomba S, Sammartino A, Di Carlo C et al (2001) Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril 76:38–43
Palomba S, Orio F Jr, Morelli M et al (2002a) Raloxifene administration in pre-menopausal women with uterine leiomyomas: a pilot study. J Clin Endocrinol Metab 87:3603–3608
Palomba S, Russo T, Orio F Jr et al (2002b) Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod 17:3213–3219
Palomba S, Orio F Jr, Russo T et al (2004) Long term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Hum Reprod 19:1308–1314
Panidis D, Vavilis D, Rousso D et al (1994) Danazol influences gonadotropin secretion acting at the hypothalamic level. Int J Obstet Gynecol 45:241–246
Parsanezhad ME, Azmoon M, Alborzi S et al (2010) A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril 93:192–198
Pourmatroud E, Hormozi L, Hemadi M et al (2012) Intravenous ascorbic acid (vitamin C) administration in myomectomy: a prospective, randomized, clinical trial. Arch Gynecol Obstet 285:111–115
Rein MS, Friedman AJ, Stuart JM, MacLaughlin DT (1990) Fibroid and myometrial steroid receptors in women treated with the gonadotropin-releasing hormone agonist leuprolide acetate. Fertil Steril 53:1018
Salama S, Nasr A, Dubey R et al (2006) Estrogen metabolite 2-methoxyestradiol induces apoptosis and inhibits cell proliferation and collagen production in rat and human leiomyoma cells: a potential medicinal treatment for uterine fibroids. J Soc Gynecol Investig 13:542–550
Sayyah-Melli M, Tehrani-Gadim S, Dastranj-Tabrizi A et al (2009) Comparison of the effect of gonadotropin-releasing hormone agonist and dopamine receptor agonist on uterine myoma growth. Histologic, sonographic, and intra-operative changes. Saudi Med J 30:1024–1033
Scialli AR, Levi AJ (2000) Intermittent leuprolide acetate for the nonsurgical management of women with leiomyomata uteri. Fertil Steril 74:540–546
Sherwin BB, Tulandi T (1996) “Add-back” estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 81:2545–2549
Shushan A, Ben-Bassat H, Mishani E et al (2007) Inhibition of leiomyoma cell proliferation in vitro by genestein and the protein tyrosine kinase inhibitor TKS050. Fertil Steril 87:127–135
Shushan A, Rojansky N, Laufer N et al (2004) The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Hum Reprod 19:1957–1967
Steinauer J, Pritts EA, Jackson R et al (2004) Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 103:1331–1336
Tiltman AJ (1985) The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol 4:89
Tsuiji K, Takeda T, Li B et al (2011) Inhibitory effect of curcumin on uterine leiomyoma cell proliferation. Gynecol Endocrinol 27:512–517
Walker CL (2002) Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. Recent Prog Horm Res 57:277–294
Wang J, Ohara N, Wang Z et al (2006) A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-1, TGF beta 3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod 21:1869–77
Wilkens J, Chwalisz K, Han C et al (2008) Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 93:4664–4671
Xu Q, Ohara N, Chen W et al (2006) Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 21:2408–2416
Yin P, Lin Z, Cheng YH, Marsh EE, Utsunomiya H, Ishikawa H, Xue Q, Reierstad S, Innes J, Thung S, Kim JJ, Xu E, Bulun SE (2007) Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promotor region in uterine leiomyoma cells. J Clin Endocrinol Metab 92:4459
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Olive, D.L. (2013). The Medical Treatment of Uterine Fibroids. In: Reidy, J., Hacking, N., McLucas, B. (eds) Radiological Interventions in Obstetrics and Gynaecology. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2013_850
Download citation
DOI: https://doi.org/10.1007/174_2013_850
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-27974-4
Online ISBN: 978-3-642-27975-1
eBook Packages: MedicineMedicine (R0)